ICPT - Intercept And Conatus In NASH And The Market Assessment
Market Assessment
2019 is seen as the year of NASH in the biotech industry. Intercept (ICPT) is expected to announce the top-line Phase 3 data readout for obeticholic acid in NASH fibrosis imminently. Likewise, top-line data readout is also expected in Q1/2019 from Conatus (CNAT). This small market cap biopharma may finally get to validate the clinical efficacy of its dual anti-apoptotic/anti-inflammatory anti-NASH drug candidate, emricasan, in Phase 2b NASH fibrosis (recently reviewed in Liver Therapy Forum). Given emricasan's history of perceived clinical disappointments, a positive clinical outcome would definitely